1111637-70-7

Basic information

• Product Name: Boronicacid,B-(2,3-dihydro-2-oxo-1H-pyrrolo[2,3-b]pyridin-5-yl)-
• Synonyms: Boronicacid,B-(2,3-dihydro-2-oxo-1H-pyrrolo[2,3-b]pyridin-5-yl)-;2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-ylboronic acid;{2-oxo-1h,2h,3h-pyrrolo[2,3-b]pyridin-5-yl}boronic acid;(2-Oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)
• CAS NO: 1111637-70-7
• Molecular Formula: C7H7BN2O3
• Molecular Weight: 177.95308
• Mol File: 1111637-70-7.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.50±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 6?+-.0.20(Predicted)
• CAS DataBase Reference: Boronicacid,B-(2,3-dihydro-2-oxo-1H-pyrrolo[2,3-b]pyridin-5-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Boronicacid,B-(2,3-dihydro-2-oxo-1H-pyrrolo[2,3-b]pyridin-5-yl)-(1111637-70-7)
• EPA Substance Registry System: Boronicacid,B-(2,3-dihydro-2-oxo-1H-pyrrolo[2,3-b]pyridin-5-yl)-(1111637-70-7)

Safety Data

• Hazardous Substances Data: 1111637-70-7(Hazardous Substances Data)

Usage

Description

Boronicacid, B-(2,3-dihydro-2-oxo-1H-pyrrolo[2,3-b]pyridin-5-yl)-, also known as Bortezomib, is a potent proteasome inhibitor with significant therapeutic potential in the treatment of multiple myeloma and mantle cell lymphoma. It functions by inhibiting the proteasome, a cellular complex responsible for protein degradation, leading to the accumulation of unwanted proteins and ultimately inducing cell death. Bortezomib has demonstrated promising results in clinical trials, resulting in its FDA approval for the treatment of these aggressive forms of cancer. However, its use must be carefully monitored due to potential side effects such as peripheral neuropathy, thrombocytopenia, and gastrointestinal issues.

Uses

Used in Oncology:
Boronicacid, B-(2,3-dihydro-2-oxo-1H-pyrrolo[2,3-b]pyridin-5-yl)is used as a proteasome inhibitor for the treatment of multiple myeloma and mantle cell lymphoma. Its mechanism of action involves the inhibition of the proteasome, leading to the accumulation of unwanted proteins and inducing cell death, making it a valuable therapeutic agent in oncology.
Used in Clinical Trials:
Boronicacid, B-(2,3-dihydro-2-oxo-1H-pyrrolo[2,3-b]pyridin-5-yl)is used as a subject of clinical trials to evaluate its efficacy and safety in treating various forms of cancer. These trials aim to determine the optimal dosage, administration, and potential side effects, ensuring that Bortezomib can be effectively and safely used in cancer treatment.
Used in Pharmaceutical Development:
Boronicacid, B-(2,3-dihydro-2-oxo-1H-pyrrolo[2,3-b]pyridin-5-yl)is used as a key component in the development of new pharmaceuticals targeting the proteasome. Researchers are exploring its potential in combination therapies and the development of novel drugs with similar mechanisms of action to enhance cancer treatment options and improve patient outcomes.
Used in Cancer Research:
Boronicacid, B-(2,3-dihydro-2-oxo-1H-pyrrolo[2,3-b]pyridin-5-yl)is used as a research tool in cancer biology to study the role of the proteasome in cancer cell survival and proliferation. Understanding the molecular mechanisms underlying its action can lead to the discovery of new targets and the development of more effective cancer therapies.
Used in Drug Monitoring and Management:
Boronicacid, B-(2,3-dihydro-2-oxo-1H-pyrrolo[2,3-b]pyridin-5-yl)is used in the monitoring and management of patients undergoing treatment with Bortezomib. Due to its potential side effects, healthcare professionals must closely monitor patients to ensure the safe and effective use of this proteasome inhibitor in cancer treatment.

Upstream product

• 183208-34-6 5-bromo-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one 

Relevant articles and documents

PYRAZOLE COMPOUNDS

The present invention is directed to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.